Author:
Altman R.D.,Abadie E.,Avouac B.,Bouvenot G.,Branco J.,Bruyere O.,Calvo G.,Devogelaer J.-P.,Dreiser R.L.,Herrero-Beaumont G.,Kahan A.,Kreutz G.,Laslop A.,Lemmel E.M.,Menkes C.J.,Pavelka K.,Van De Putte L.,Vanhaelst L.,Reginster J.-Y.
Subject
Orthopedics and Sports Medicine,Biomedical Engineering,Rheumatology
Reference35 articles.
1. Measurement of structural progression in osteoarthritis of the hip: the Barcelona consensus group;Altman;Osteoarthritis Cartilage,2004
2. New perspectives in the management of osteoarthritis structure modification: facts or fantasy?;Reginster;J Rheumatol,2003
3. Guidance for the industry. Clinical development programs for drugs, devices and biological products intended for the treatment of osteoarthritis. US Department of Health and Human Services. Food and Drug Administration, Center for Drug Evaluation and Research, July 1999. Available from: http://www.fda.gov/cder/guidance/2199dft.htm.
4. Points to consider on clinical investigation of medicinal products used in the treatment of osteoarthritis. European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products, July 1998. Available from: http://www.emea.eu.int/pdfs/human/ewp/078497en.pdf.
5. Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis;Abadie;Osteoarthritis Cartilage,2004
Cited by
56 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献